July 11th, 2024 | 06:55 CEST
Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments
Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
EVOTEC SE INH O.N. | DE0005664809 , VARTA AG O.N. | DE000A0TGJ55 , CARBON DONE RIGHT DEVELOPMENTS INC | CA14109M1023
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Evotec: News frenzy continues
The new Evotec Management Board is kicking off with a flurry of news. The partnership with Pfizer announced yesterday is the latest success story - we first reported on the cooperation in biosimilars yesterday. The biotech company's share price reacted with a jump of around 4% and is again approaching the resistance level at EUR 10. A multi-year research collaboration, as well as an option and license agreement in the areas of metabolic and infectious diseases, have been agreed with Pfizer. The research work will take place at Evotec's facilities in France. Evotec will receive research payments from Pfizer and be eligible for potential milestone and license payments if the projects succeed.
Pfizer manager Dr. Luca Mollo: "We are excited to collaborate with Evotec to conduct research that can help develop new approaches to treat common metabolic and infectious diseases that affect millions of patients worldwide. France has developed a strong biopharmaceutical ecosystem, and we are delighted to work with Evotec to expand our joint commitment to advancing scientific research into diseases with unmet needs."
Carbon Done Right Developments: Share price fireworks after AIM listing?
Milestone payments are also regularly received by Carbon Done Right Developments Inc. The Company is currently building an exciting platform around climate protection and carbon credits and is establishing itself in a market worth billions. The market capitalization of the Canadian company is presently less than CAD 5 million. Preparations are underway for a listing on the Alternative Investment Market (AIM) of the London Stock Exchange, which should significantly increase awareness of the Company and its shares. The British oil company BP is also a customer.
The core business is the reforestation of large areas and the creation of marine biotopes, for example, in Asia, Africa, and South America. Carbon Done Right Developments then uses artificial intelligence and big data to monitor and document carbon sequestration. The CO2 certificates generated in this way are sold to companies worldwide.
This year, the business model has already been expanded to include a London-based blockchain-supported trading platform for emission certificates. The Company is thus building an entire ecosystem for emissions savings and trading. If the next milestones are reached, the share will likely no longer be as cheap as it currently is.
Varta: Is Porsche becoming a game changer?
It has been a while since we have read such positive news from Varta. At the end of last week, the battery manufacturer announced that it was negotiating the sale of a majority stake in the large-format lithium-ion cell division (V4Drive) with Porsche. A non-binding term sheet had been signed. The V4Drive business is to be bundled in V4Drive Battery GmbH, and Porsche is to participate via a capital increase.
However, this does not change the fact that Varta is still having serious difficulties. The existing IDW-S6 report is still being updated. In addition, Varta is still working on options for potential recapitalization and financing measures.
Therefore, analysts are also hitting the euphoria brake. Following the Porsche report, Warburg confirmed its "Sell" recommendation. Of course, the spin-off of the V4Drive business is fundamentally positive, but it has little impact on Varta's restructuring efforts. Therefore, they see the Varta share as fairly valued at EUR 8.
Even for Berenberg, the collaboration with Porsche would not be a game changer. According to analysts, Varta is currently a "Hold". The target price has been reduced from EUR 22 to EUR 15. The shares of the former German battery hopeful are trading at EUR 10.
Varta is probably still only for real gamblers, as the Company's future is anything but secure. The Carbon Done Right Developments share is anything but expensive. If there is more positive news in the coming months and the share is listed on AIM, it could go up quickly and powerfully. At Evotec, the latest newsflow is encouraging. If the momentum continues, investors should soon forget the problems of the first half of the year.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
